This ongoing trial specifically aims to evaluate the effect of prostate-specific antigen (PSA) testing on PCa mortality and currently reports a 20% relative reduction in PCa mortality for men randomized to screening [2,3,4,5] Available online: (www.prias-project.org), (accessed on 1 February 2022). This evidence concerns the gene KLK3 and posterior cortical atrophy.